Login to Your Account



Earnings Roundup


Monday, February 13, 2012
• InterMune Inc., of Brisbane, Calif., reported fourth-quarter product revenue totaling $7.8 million, consisting of $2.7 million for sales of idiopathic pulmonary fibrosis drug Esbriet (pirfenidone) in Europe. The drug was launched in Germany last year and, as of Jan. 5, about 612 patients had been prescribed Esbriet.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription